# US 2020/0268666 A1 · Polynucleotides encoding coagulation factor viii

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0268666 A1
- Document ID: US20200268666A1
- Status: Published application
- Kind: A1
- Application number: 16/621,514
- Filed: 2018-06-13
- Published: 2020-08-27
- Earliest claimed: 2017-06-14
- Assignees: ModernaTX, Inc.; Seattle Children's Hospital d/b/a Seattle Children's Research Institute
- Applicants: ModernaTX, Inc.; Seattle Children's Hospital d/b/a Seattle Children's Research Institute
- Inventors: Raj Rajendran; Paolo G. V. Martini; Carol H. Miao
- Web page: https://patentgrep.com/patent/US20200268666A1

## CPC

- A61K 9/1272: comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers (lipids as modifying agents {A61K47/543})
- A61K 9/1617: {Organic compounds, e.g. phospholipids, fats}
- A61K 38/37: Factors VIII
- A61P 7/04: Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- C07K 14/755: Factors VIII {, e.g. factor VIII C (AHF), factor VIII Ag (VWF)}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The invention relates to mRNA therapy for the treatment of Hemophilia A. mRNAs for use in the invention, when administered in vivo, encode Factor VIII, isoforms thereof, functional fragments thereof, and fusion proteins comprising Factor VIII. mRNAs of the invention are preferably encapsulated in lipid nanoparticles (LNPs) to effect efficient delivery to cells and/or tissues in subjects, when administered thereto. mRNA therapies of the invention increase and/or restore deficient levels of Factor VIII expression and/or activity in subjects. mRNA therapies of the invention further decrease levels of toxic metabolites associated with deficient Factor VII I activity in subjects.

## Claims

### Claim at position 1

-133. (canceled)

### Claim 134

A pharmaceutical composition comprising a lipid nanoparticle, wherein the lipid nanoparticle comprises a compound having the formula (I)
or a salt or stereoisomer thereof, wherein
R1 is selected from the group consisting of C5-20 alkyl, C5-20 alkenyl, —R*YR″, —YR″, and —R″M′R′;
R2 and R3 are independently selected from the group consisting of H, C1-14 alkyl, C2-14 alkenyl, —R*YR″, —YR″, and —R*OR″, or R2 and R3, together with the atom to which they are attached, form a heterocycle or carbocycle;
R4 is selected from the group consisting of a C3-6 carbocycle, —(CH2)nQ, —(CH2)nCHQR,
—CHQR, —CQ(R)2, and unsubstituted C1-6 alkyl, where Q is selected from a carbocycle, heterocycle, —OR, —O(CH2)nN(R)2, —C(O)OR, —OC(O)R, —CX3, —CX2H, —CXH2, —CN, —N(R)2, —C(O)N(R)2, —N(R)C(O)R, —N(R)S(O)2R, —N(R)C(O)N(R)2, —N(R)C(S)N(R)2, and —C(R)N(R)2C(O)OR, and each n is independently selected from 1, 2, 3, 4, and 5;
each R5 is independently selected from the group consisting of C1-3 alkyl, C2-3 alkenyl, and H;
each R6 is independently selected from the group consisting of C1-3 alkyl, C2-3 alkenyl, and H;
M and M′ are independently selected from —C(O)O—, —OC(O)—, —C(O)N(R′)—, —N(R′)C(O)—, —C(O)—, —C(S)—, —C(S)S—, —SC(S)—, —CH(OH)—, —P(O)(OR′)O—, —S(O)2—, an aryl group, and a heteroaryl group;
R7 is selected from the group consisting of C1-3 alkyl, C2-3 alkenyl, and H;
each R is independently selected from the group consisting of C1-3 alkyl, C2-3 alkenyl, and H;
each R′ is independently selected from the group consisting of C1-18 alkyl, C2-18 alkenyl, —R*YR″, —YR″, and H;
each R″ is independently selected from the group consisting of C3-14 alkyl and C3-14 alkenyl;
each R* is independently selected from the group consisting of C1-12 alkyl and C2-12 alkenyl;
each Y is independently a C3-6 carbocycle;
each X is independently selected from the group consisting of F, Cl, Br, and I; and
m is selected from 5, 6, 7, 8, 9, 10, 11, 12, and 13; and
provided when R4 is —(CH2)nQ, —(CH2)nCHQR, —CHQR, or —CQ(R)2, then (i) Q is not —N(R)2 when n is 1, 2, 3, 4 or 5, or (ii) Q is not 5, 6, or 7-membered heterocycloalkyl when n is 1 or 2,
wherein the lipid nanoparticle comprises an mRNA that comprises an open reading frame (ORF) encoding a human Coagulation Factor VIII (Factor VIII) polypeptide, wherein the composition is suitable for administration to a human subject in need of treatment for Hemophilia A.

### Claim 135 (depends on 134)

The pharmaceutical composition of claim 134, wherein the lipid nanoparticle comprises the compound is of Formula (IA):
or a salt or stereoisomer thereof, wherein
l is selected from 1, 2, 3, 4, and 5;
m is selected from 5, 6, 7, 8, and 9;
M1 is a bond or M′;
R4 is unsubstituted C1-3 alkyl, or —(CH2)nQ, in which Q is OH, —NHC(S)N(R)2, —NHC(O)N(R)2, —N(R)C(O)R, —N(R)S(O)2R, —N(R)R8, —NHC(═NR9)N(R)2, —NHC(═CHR9)N(R)2, —OC(O)N(R)2, —N(R)C(O)OR, heteroaryl, or heterocycloalkyl; M and M′ are independently selected from —C(O)O—, —OC(O)—, —C(O)N(R′)—, —P(O)(OR′)O—, —S—S—, an aryl group, and a heteroaryl group; and
R2 and R3 are independently selected from the group consisting of H, C1-14 alkyl, and C2-14 alkenyl.

### Claim 136 (depends on 134)

The pharmaceutical composition of claim 134, wherein m is 5, 7, or 9.

### Claim 137 (depends on 134)

The pharmaceutical composition of claim 134, wherein the compound is of Formula (II)
or a salt or stereoisomer thereof, wherein
l is selected from 1, 2, 3, 4, and 5;
M1 is a bond or M′;
R4 is unsubstituted C1-3 alkyl, or —(CH2)nQ, in which n is 2, 3, or 4, and Q is OH, —NHC(S)N(R)2, —NHC(O)N(R)2, —N(R)C(O)R, —N(R)S(O)2R, —N(R)R8, —NHC(═NR9)N(R)2, —NHC(═CHR9)N(R)2, —OC(O)N(R)2, —N(R)C(O)OR, heteroaryl, or heterocycloalkyl;
M and M′ are independently selected from —C(O)O—, —OC(O)—, —C(O)N(R′)—, —P(O)(OR′)O—, —S—S—, an aryl group, and a heteroaryl group; and
R2 and R3 are independently selected from the group consisting of H, C1-14 alkyl, and C2-14 alkenyl.

### Claim 138 (depends on 135)

The pharmaceutical composition of claim 135, wherein M1 is M′.

### Claim 139 (depends on 138)

The pharmaceutical composition of claim 138, wherein M and M′ are independently —C(O)O— or —OC(O)—.

### Claim 140 (depends on 135)

The pharmaceutical composition of claim 135, wherein l is 1, 3, or 5.

### Claim 141 (depends on 134)

The pharmaceutical composition of claim 134, wherein the compound is selected from the group consisting of Compound 1 to Compound 232, salts and stereoisomers thereof, and any combination thereof.

### Claim 142 (depends on 141)

The pharmaceutical composition of claim 141, wherein the compound is Compound 18, a salt or a stereoisomer thereof, or any combination thereof.

### Claim 143 (depends on 134)

A method of expressing a human Factor VIII polypeptide in a human subject in need thereof comprising administering to the subject an effective amount of the pharmaceutical composition of claim 134, wherein the pharmaceutical composition is suitable for administrating as a single dose or as a plurality of single unit doses to the subject.

### Claim 144 (depends on 134)

A method of treating, preventing or delaying the onset and/or progression of Hemophilia A signs or symptoms in a human subject in need thereof comprising administering to the subject an effective amount of the pharmaceutical composition of claim 134, wherein the administration treats, prevents or delays the onset and/or progression of one or more of the signs or symptoms of Hemophilia A in the subject.

### Claim 145 (depends on 134)

A method for the treatment of Hemophilia A, comprising administering to a human subject suffering from Hemophilia A a single intravenous dose of the pharmaceutical composition of claim 134.

### Claim 146 (depends on 134)

A method of improving the clotting rate in a human subject comprising administering to the subject an effective amount of the pharmaceutical composition of claim 134, wherein the administration improves the clotting rate in the subject.

### Claim 147 (depends on 146)

The method of claim 146, wherein the clotting rate is improved by at least 10%, at least 20%, at least 30%, at least 40%, or at least 50%, as compared to the clotting rate in a human subject untreated for Hemophilia A, for at least 24 hours, at least 48 hours, at least 72 hours, at least 96 hours, or at least 120 hours post-administration.

### Claim 148 (depends on 134)

A method of increasing the level of Factor VIII activity in a human subject comprising administering to the subject an effective amount of the pharmaceutical composition of claim 134, wherein the administration increases the level of Factor VIII activity in the subject.
